Dupixent predicted to be blockbuster for Sanofi
Novo hopes data will justify higher price compared with rival.
Trials will resume once safety protocols have been reviewed.
NICE unconvinced by survival data from Ipsen and Sanofi drugs
Biosimilar Lantus is causing rivals to cut prices to compete
Collaboration will develop drugs for inflammatory diseases
Regulator drops demand for further phase 3 trial.
Biotech’s Flublok is only FDA-approved cell-based flu jab